ECSP055588A - Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico - Google Patents

Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico

Info

Publication number
ECSP055588A
ECSP055588A EC2005005588A ECSP055588A ECSP055588A EC SP055588 A ECSP055588 A EC SP055588A EC 2005005588 A EC2005005588 A EC 2005005588A EC SP055588 A ECSP055588 A EC SP055588A EC SP055588 A ECSP055588 A EC SP055588A
Authority
EC
Ecuador
Prior art keywords
quinoxaline
methyl
fluorobencil
dihidroxi
octil
Prior art date
Application number
EC2005005588A
Other languages
English (en)
Inventor
John Charles Kath
Christopher Stanley Poss
Jane Li Zheng
Bryan Li Zhengong
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055588A publication Critical patent/ECSP055588A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxaline-2-carboxílico, útiles en el tratamiento o prevención de un trastorno o afección por medio de la antagonización del receptor CCR1, y sus métodos de preparación y uso.
EC2005005588A 2002-08-12 2005-02-03 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico ECSP055588A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
ECSP055588A true ECSP055588A (es) 2005-04-18

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005588A ECSP055588A (es) 2002-08-12 2005-02-03 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico

Country Status (22)

Country Link
US (1) US20040072834A1 (es)
EP (1) EP1539715A1 (es)
JP (1) JP2005538130A (es)
AP (1) AP2005003226A0 (es)
AR (1) AR040839A1 (es)
AU (1) AU2003250450A1 (es)
BR (1) BR0313378A (es)
CA (1) CA2494776A1 (es)
EC (1) ECSP055588A (es)
GT (1) GT200300169A (es)
IL (1) IL166548A0 (es)
IS (1) IS7674A (es)
MX (1) MXPA05001781A (es)
NO (1) NO20050540L (es)
OA (1) OA12894A (es)
PA (1) PA8580401A1 (es)
PE (1) PE20040866A1 (es)
TN (1) TNSN05035A1 (es)
TW (1) TW200407316A (es)
UY (1) UY27928A1 (es)
WO (1) WO2004014875A1 (es)
ZA (1) ZA200500768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731538B2 (ja) 2009-12-23 2015-06-10 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｃｒｔｈ２モジュレーター
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1998038167A1 (en) * 1997-02-26 1998-09-03 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
UA57824C2 (uk) * 1998-02-05 2003-07-15 Пфайзер Продактс Інк. Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
IS7674A (is) 2005-01-27
TW200407316A (en) 2004-05-16
ZA200500768B (en) 2006-07-26
AP2005003226A0 (en) 2005-03-31
JP2005538130A (ja) 2005-12-15
BR0313378A (pt) 2005-07-12
UY27928A1 (es) 2004-03-31
NO20050540L (no) 2005-03-10
OA12894A (en) 2006-10-13
PA8580401A1 (es) 2004-02-16
CA2494776A1 (en) 2004-02-19
WO2004014875A1 (en) 2004-02-19
US20040072834A1 (en) 2004-04-15
GT200300169A (es) 2004-05-12
MXPA05001781A (es) 2005-04-25
PE20040866A1 (es) 2004-11-26
IL166548A0 (en) 2006-01-15
EP1539715A1 (en) 2005-06-15
AR040839A1 (es) 2005-04-20
AU2003250450A1 (en) 2004-02-25
TNSN05035A1 (fr) 2007-05-14

Similar Documents

Publication Publication Date Title
PA8579601A1 (es) Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
AR037109A1 (es) Uso de flibanserina
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2007073497A3 (en) Calcium channel antagonists
IS2733B (is) Afleiður af díoxan-2-alkýlkarbamötum, framleiðsluaðferð þeirra, milliefni notuð við framleiðsluna, og notkun þeirra í meðferð.
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
CL2003001415A1 (es) Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
CL2006003736A1 (es) Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
EP1967264A4 (en) DENITRIFICATION CATALYST, DENITRIFICATION CATALYST WITH WAVE STRUCTURE AND DENITRIFICATION METHOD THEREFOR
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
SI1276476T1 (sl) Uporaba bradikardnih snovi pri zdravljenju miokardnih bolezni, povezanih s hipertrofijo, in nove kombinacije zdravil
ECSP055588A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico
BRPI0514579A (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DOP2003000682A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,3-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico